Intentional Enneking-inappropriate surgery and high-energy particle therapy for unresectable osteogenic sarcoma of the spine: a retrospective study.

high-energy particle oncology osteosarcoma spine tumor

Journal

Journal of neurosurgery. Spine
ISSN: 1547-5646
Titre abrégé: J Neurosurg Spine
Pays: United States
ID NLM: 101223545

Informations de publication

Date de publication:
27 Sep 2024
Historique:
received: 04 01 2024
accepted: 31 05 2024
medline: 27 9 2024
pubmed: 27 9 2024
entrez: 27 9 2024
Statut: aheadofprint

Résumé

The aim of this study was to compare the outcome of intralesional gross-total resection (GTR) followed by high-energy particle therapy with en bloc and intralesional resections. A retrospective study of patients diagnosed with primary osteogenic sarcoma (OGS) of the spine between 2009 and 2020 was conducted. Demographic information, including age, affected site, tumor volume, and Weinstein-Boriani-Biagini stage, was collected. Additionally, information on metastases at diagnosis, length of stay, operating time, complications, planned surgical treatment, and radiotherapy was also collected. Outcome measures, including local recurrence (LR) and disease-specific survival (DSS), were compared using Kaplan-Meier curves. In total, 20 patients with a median age of 38 (IQR 23-60) years were included. The median follow-up was 15.7 (IQR 6.3-36.9) months. Eight patients underwent en bloc resection with a 38% (3 patients) LR rate and a median DSS of 26.4 months. Four patients received adjuvant high-energy particle therapy after planned GTR. Their median follow-up was 36 months; none of these patients experienced LR. Both the 1-year and 3-year DSSs were 100%. Another 8 patients underwent intralesional resection. Six of the 8 patients (75%) died of their disease, with a median survival of 7.3 (IQR 4.7-14) months. GTR combined with adjuvant high-energy particle therapy appears to be a safe and effective alternative approach for patients with OGS of the spine when en bloc resection is not feasible. The results demonstrated a 3-year DSS of 100% and no major surgical complications.

Identifiants

pubmed: 39332038
doi: 10.3171/2024.5.SPINE231401
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Auteurs

Gisberto Evangelisti (G)

1Department of Spine Surgery, Orthopaedic Institute Rizzoli, Bologna, Italy.

Luigi Falzetti (L)

1Department of Spine Surgery, Orthopaedic Institute Rizzoli, Bologna, Italy.

Franziska C S Altorfer (FCS)

2University Spine Center Zürich, Balgrist University Hospital, University of Zurich, Switzerland.

Stefano Bandiera (S)

1Department of Spine Surgery, Orthopaedic Institute Rizzoli, Bologna, Italy.

Giovanni Barbanti Brodano (G)

1Department of Spine Surgery, Orthopaedic Institute Rizzoli, Bologna, Italy.

Marco Cianchetti (M)

3Department of Proton Therapy, Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy.

Maria R Fiore (MR)

7National Centre for Oncological Treatment, CNAO, Pavia, Italy.

Emanuela Palmerini (E)

4Department of Bone and Soft Tissue Oncology, Orthopaedic Institute Rizzoli, Bologna, Italy.

Joseph H Schwab (JH)

5Orthopaedic Spine Center, Massachusetts General Hospital, Boston, Massachusetts.

Stefano Boriani (S)

6GSpine4, Orthopaedic Institute Galeazzi, Milan, Italy; and.

Alessandro Gasbarrini (A)

6GSpine4, Orthopaedic Institute Galeazzi, Milan, Italy; and.

Classifications MeSH